{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:37:37Z","timestamp":1792424257520,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2022\/04796-3"],"award-info":[{"award-number":["2022\/04796-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02533-z","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:07:21Z","timestamp":1729004841000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad\u00ae (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases"],"prefix":"10.1007","volume":"41","author":[{"given":"Gabriela Cardoso","family":"de Arruda Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna Nayara Silva","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora Manzato","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monaliza","family":"\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca Ribeiro","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Carlos Cardoso","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner Jos\u00e9","family":"F\u00e1varo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"10","key":"2533_CR1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014\u201322.","journal-title":"Nat Immunol"},{"issue":"6230","key":"2533_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74\u201380.","journal-title":"Science"},{"issue":"8","key":"2533_CR3","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1172\/JCI89717","volume":"127","author":"MF Chevalier","year":"2017","unstructured":"Chevalier MF, Trabanelli S, Racle J, Salom\u00e9 B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derr\u00e9 L. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916\u201329.","journal-title":"J Clin Invest"},{"issue":"3","key":"2533_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/ncpuro1061","volume":"5","author":"EM Messing","year":"2008","unstructured":"Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nat Clin Pract Urol. 2008;5(3):117.","journal-title":"Nat Clin Pract Urol"},{"key":"2533_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2533_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447\u201361.","journal-title":"Eur Urol"},{"key":"2533_CR7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","volume":"3","author":"AM Kamat","year":"2020","unstructured":"Kamat AM, Lerner SP, O\u2019Donnell M, Georgieva MV, Yang M, Inman BA, et al. Evidence-based assessment of current and emerging bladder-sparing therapies for non-muscle-invasive bladder cancer after bacillus calmette-guerin therapy: a systematic review and meta-analysis. Eur Urol Oncol. 2020;3:318\u201340.","journal-title":"Eur Urol Oncol"},{"key":"2533_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1080\/14737140.2022.2046466","volume":"22","author":"N Lobo","year":"2022","unstructured":"Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2022;22:361\u201370.","journal-title":"Expert Rev Anticancer Ther"},{"key":"2533_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imr.12531","volume":"276","author":"AH Sharpe","year":"2017","unstructured":"Sharpe AH. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276:5\u20138.","journal-title":"Immunol Rev"},{"key":"2533_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/s41467-021-21619-0","volume":"12","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi T, Hoki T, Oba T, Jain V, Chen H, Attwood K, et al. T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nat Commun. 2021;12:1402.","journal-title":"Nat Commun"},{"key":"2533_CR11","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1046\/j.1464-410x.1998.00628.x","volume":"81","author":"P Allard","year":"1998","unstructured":"Allard P, Bernard P, Fradet Y, T\u00eatu B. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol. 1998;81:692\u20138.","journal-title":"Br J Urol"},{"key":"2533_CR12","first-page":"65.e19","volume":"33","author":"LM Krabbe","year":"2015","unstructured":"Krabbe LM, Svatek RS, Shariat SF, Messing E, Lotan Y. Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort. Urol Oncol Semin Orig Investig. 2015;33:65.e19-65.e25.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"2533_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.urology.2015.05.040","volume":"86","author":"EJ Pietzak","year":"2015","unstructured":"Pietzak EJ, Mucksavage P, Guzzo TJ, Malkowicz SB. Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology. 2015;86:968\u201373.","journal-title":"Urology"},{"key":"2533_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153\u201367.","journal-title":"Nat Rev Immunol"},{"key":"2533_CR15","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 2018;115:E4041\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2533_CR16","first-page":"9","volume":"2018","author":"RM Awad","year":"1977","unstructured":"Awad RM, De Vlaeminck Y, Maebe J, Goyvaerts C, Breckpot K. Turn back the TIMe: targeting tumor infiltrating myeloid cells to revert cancer progression. Front Immunol. 1977;2018:9.","journal-title":"Front Immunol"},{"key":"2533_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2018.00003","volume":"8","author":"T Fujimura","year":"2018","unstructured":"Fujimura T, Kambayashi Y, Fujisawa Y, Hidaka T, Aiba S. Tumor-associated macrophages: therapeutic targets for skin cancer. Front Oncol. 2018;8:3.","journal-title":"Front Oncol"},{"key":"2533_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382.","journal-title":"Nat Rev Immunol"},{"key":"2533_CR19","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1038\/s41467-021-23164-2","volume":"12","author":"YC Wang","year":"2021","unstructured":"Wang YC, Wang X, Yu J, Ma F, Li Z, Zhou Y, et al. Targeting monoamine oxidase a-regulated tumor-associated macrophage polarization for cancer immunotherapy. Nat Commun. 2021;12:3530.","journal-title":"Nat Commun"},{"key":"2533_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1096\/fasebj.9.8.7768351","volume":"9","author":"TP Singer","year":"1995","unstructured":"Singer TP, Ramsay RR. Monoamine oxidases: old friends hold many surprises. FASEB J. 1995;9:605\u201310.","journal-title":"FASEB J"},{"key":"2533_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2174\/0929867305666220314202430","volume":"5","author":"J Wouers","year":"1998","unstructured":"Wouers J. Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem. 1998;5:137\u201362.","journal-title":"Curr Med Chem"},{"key":"2533_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev.neuro.22.1.197","volume":"22","author":"JC Shih","year":"1999","unstructured":"Shih JC, Chen K, Ridd M. Monoamine oxidase: from genes to behavior. Ann Rev Neurosci. 1999;22:197\u2013217.","journal-title":"Ann Rev Neurosci"},{"key":"2533_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2164-9-134","volume":"9","author":"L Rybaczyk","year":"2008","unstructured":"Rybaczyk L, Bashaw M, Pathak D, Huang K. An indicator of cancer: downregulation of monoamine oxidase-a in multiple organs and species. BMC Genom. 2008;9:134.","journal-title":"BMC Genom"},{"key":"2533_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/936486","volume":"2012","author":"A Alfadda","year":"2012","unstructured":"Alfadda A, Sallam R. Reactive oxygen species in health and disease. J Biomed Biotechnol. 2012;2012: 936486.","journal-title":"J Biomed Biotechnol"},{"key":"2533_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.imlet.2020.04.002","volume":"223","author":"Y Yang","year":"2020","unstructured":"Yang Y, Feng R, Wang YZ, Sun HW, Zou QM, Li HB. Toll-like receptors: triggers of regulated cell death and promising targets for cancer therapy. Immunol Lett. 2020;223:1\u20139.","journal-title":"Immunol Lett"},{"key":"2533_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.phrs.2019.03.001","volume":"154","author":"C Bourquin","year":"2020","unstructured":"Bourquin C, Pommier A, Hotz C. Harnessing the immune system to fight cancer with toll-like receptor and RIG-I-like receptor agonists. Pharmacol Res. 2020;154:104.","journal-title":"Pharmacol Res"},{"issue":"24","key":"2533_CR27","doi-asserted-by":"publisher","first-page":"17535","DOI":"10.3390\/ijms242417535","volume":"24","author":"JCC Alonso","year":"2023","unstructured":"Alonso JCC, de Souza BR, Reis IB, de Arruda Camargo GC, Oliveira G, Salmazo MIBF, Gon\u00e7alves JM, Castro Roston JR, Caria PHF, Santos AS, Freitas LLL, Billis A, Dur\u00e1n N, F\u00e1varo WJ. Oncotherad\u00ae(MRB-CFI-1) nanoimmunotherapy: a promising strategy to treat bacillus calmette-guerin-unresponsive non-muscle-invasive bladder cancer: crosstalk among T-cell CX3CR1, immune checkpoints, and the toll-like receptor 4 signaling pathway. Int J Mol Sci. 2023;24(24):17535.","journal-title":"Int J Mol Sci"},{"key":"2533_CR28","doi-asserted-by":"publisher","DOI":"10.1088\/1742-6596\/1323\/1\/012022","volume":"1323","author":"PK B\u00f6ckelmann","year":"2019","unstructured":"B\u00f6ckelmann PK, Tizziani SHS, Dur\u00e1n N, F\u00e1varo WJ. New therapeutic perspective for bladder cancer in dogs: toxicological and clinical effects of oncotherad nanostructured immunotherapy. J Phys Conf Ser. 2019;1323: 012022.","journal-title":"J Phys Conf Ser"},{"key":"2533_CR29","doi-asserted-by":"publisher","DOI":"10.1088\/1742-6596\/1323\/1\/012018","volume":"1323","author":"N Dur\u00e1n","year":"2019","unstructured":"Dur\u00e1n N, Dias QC, F\u00e1varo WJ. Oncotherad: a new nanobiological response modifier, its toxicological and anticancer activities. J Phys Conf Ser. 2019;1323: 012018.","journal-title":"J Phys Conf Ser"},{"key":"2533_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e16000","volume":"37","author":"WJ F\u00e1varo","year":"2019","unstructured":"F\u00e1varo WJ, Iantas SR, Gon\u00e7alves JM, Socca EAR, Dur\u00e1n N, Billis A, et al. Single-arm phase I\/II study of the safety and efficacy of oncotherad immunomodulator in patients BCG-refractory or relapsed non-muscle invasive bladder cancer. J Clin Oncol. 2019;37: e16000.","journal-title":"J Clin Oncol"},{"key":"2533_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e16004","volume":"37","author":"WJ F\u00e1varo","year":"2019","unstructured":"F\u00e1varo WJ, Iantas SR, Gon\u00e7alves JM, Dias QC, Reis IB, Billis A, Dur\u00e1n N, Alonso JCC. Role of oncotherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK\/RANKL signaling: new therapeutic perspective for non-muscle invasive bladder cancer. J Clin Oncol. 2019;37: e16004.","journal-title":"J Clin Oncol"},{"key":"2533_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2022.101762","volume":"76","author":"IB Reis","year":"2022","unstructured":"Reis IB, Tibo LHS, Socca EAR, de Souza BR, Dur\u00e1n N, F\u00e1varo WJ. Oncotherad\u00ae (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of toll-like signaling pathway. Tissue Cell. 2022;76: 101762.","journal-title":"Tissue Cell"},{"key":"2533_CR33","unstructured":"F\u00e1varo, W.J., Dur\u00e1n-Caballero, N.E. (2021) Method for producing a nanostructured complex (CFI-1), a protein-associated nanostructured complex (MRB-CFI-1) and use. U.S. Patent, Application no. 17\/236,848."},{"key":"2533_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2022.101988","volume":"80","author":"WJ F\u00e1varo","year":"2023","unstructured":"F\u00e1varo WJ, Alonso JCC, de Souza BR, Reis IB, Gon\u00e7alves JM, Deckmann AC, Oliveira G, Dias QC, Dur\u00e1n N. New synthetic nano-immunotherapy (OncoTherad\u00ae) for non-muscle invasive bladder cancer: its synthesis, characterization and anticancer property. Tissue Cell. 2023;80: 101988.","journal-title":"Tissue Cell"},{"key":"2533_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2021.4844","volume":"47","author":"JJ Name","year":"2021","unstructured":"Name JJ, Vasconcelos AR, Souza ACR, F\u00e1varo WJ. Vitamin D, zinc and glutamine: synergistic action with oncotherad immunomodulator in interferon signaling and COVID-19 (Review). Int J Mol Med. 2021;47:11.","journal-title":"Int J Mol Med"},{"key":"2533_CR36","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1007\/s00432-022-04449-5","volume":"149","author":"IB Reis","year":"2023","unstructured":"Reis IB, Tibo LHS, Souza BR, Dur\u00e1n N, F\u00e1varo WJ. OncoTherad\u00ae is an immunomodulator of biological response that downregulate RANK\/RANKL signaling pathway and PD-1\/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. J Cancer Res Clin Oncol. 2023;149:5025\u201336.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2533_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110723","volume":"123","author":"BR Souza","year":"2023","unstructured":"Souza BR, Reis IB, Camargo GCA, Oliveira G, Dias QD, Dur\u00e1n N, F\u00e1varo WJ. A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad\u00aeimmunotherapy associated with platelet-rich plasma. Int Immunopharmacol. 2023;123: 110723.","journal-title":"Int Immunopharmacol"},{"key":"2533_CR38","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein JI, Amin MB, Reuter VR, Mostofi FK. The world health organization\/international society of urologic pathology consensus classification of urothelial (transitional) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435\u201348.","journal-title":"Am J Surg Pathol"},{"key":"2533_CR39","doi-asserted-by":"publisher","first-page":"e56025","DOI":"10.3791\/56025","volume":"125","author":"JX Yuan","year":"2017","unstructured":"Yuan JX, Munson JM. Quantitative Immunohistochemistry of the cellular microenvironment in patient glioblastoma resections. J Vis Exp. 2017;125:e56025. https:\/\/doi.org\/10.3791\/56025.","journal-title":"J Vis Exp"},{"key":"2533_CR40","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jhep.2014.02.025","volume":"60","author":"J Li","year":"2014","unstructured":"Li J, Yang X-M, Wang Y-H, Feng M-X, Liu X-J, Zhang Y-L, et al. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 2014;60:1225\u201334.","journal-title":"J Hepatol"},{"key":"2533_CR41","doi-asserted-by":"publisher","first-page":"143e189","DOI":"10.1016\/j.ejmech.2016.09.023","volume":"125","author":"J Akhtar","year":"2017","unstructured":"Akhtar J, Khan AA, Ali Z, Haider MR, Yar S. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Europ J Med Chem. 2017;125:143e189.","journal-title":"Europ J Med Chem"},{"key":"2533_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39\u201351.","journal-title":"Cell"},{"key":"2533_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/457036b","volume":"457","author":"A Mantovani","year":"2009","unstructured":"Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457:36\u20137.","journal-title":"Nature"},{"key":"2533_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc2618","volume":"9","author":"JA Joyce","year":"2009","unstructured":"Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239\u201352.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2533_CR45","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.imbio.2011.02.001","volume":"216","author":"MB Maniecki","year":"2011","unstructured":"Maniecki MB, Etzerodt A, Moestrup SK, M\u00f8ller HJ, Graversen JH. Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiol Immunobiol. 2011;216(7):882\u201390.","journal-title":"Immunobiol Immunobiol"},{"issue":"10","key":"2533_CR46","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1111\/pin.13144","volume":"71","author":"E Matsubara","year":"2021","unstructured":"Matsubara E, Komohara Y, Shinchi Y, Mito R, Fujiwara Y, Ikeda K, Shima T, Shimoda M, Kanai Y, Sakagami T, Suzuki M. CD163-positive cancer cells are a predictor of a worse clinical course in lung adenocarcinoma. Pathol Int. 2021;71(10):666\u201373.","journal-title":"Pathol Int"},{"issue":"5","key":"2533_CR47","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/j.clgc.2023.05.004","volume":"21","author":"Y Kobayashi","year":"2023","unstructured":"Kobayashi Y, Arai H, Hamamoto Y, Yoshida K, Shimizu S, Yasuhara Y, Ichimaru N. High infiltration of CD163-positive macrophages in intratumor compartment predicts poor prognosis in patients with upper urinary tract urothelial carcinoma and radical nephroureterectomy. Clin Genitourin Cancer. 2023;21(5):e386\u201393.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"2533_CR48","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","volume":"16","author":"H Yagi","year":"2004","unstructured":"Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, Maeda M, Onodera M, Uchiyama T, Fujii S, Sakaguchi S. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004;16(11):1643\u201356.","journal-title":"Int Immunol"},{"key":"2533_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/nri2061","volume":"7","author":"D Campbell","year":"2007","unstructured":"Campbell D, Ziegler S. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol. 2007;7:305\u201310.","journal-title":"Nat Rev Immunol"},{"key":"2533_CR50","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318.","journal-title":"Cell Res"},{"issue":"7","key":"2533_CR51","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.cell.2007.04.034","volume":"129","author":"T Zuo","year":"2007","unstructured":"Zuo T, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2\/ErbB2 oncogene. Cell. 2007;129(7):1275\u201386.","journal-title":"Cell"},{"issue":"8","key":"2533_CR52","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.4049\/jimmunol.180.8.5163","volume":"180","author":"GY Chen","year":"2008","unstructured":"Chen GY, Chen C, Wang L, Chang X, Zheng P, Liu Y. Cutting edge: broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol. 2008;180(8):5163\u20136. https:\/\/doi.org\/10.4049\/jimmunol.180.8.5163.","journal-title":"J Immunol"},{"key":"2533_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1479-5876-6-19","volume":"6","author":"V Karanikas","year":"2008","unstructured":"Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, Kerenidi T, Barda AK, Gourgoulianis KI, Germenis AE. Foxp3 expression in human cancer cells. J Transl Med. 2008;6:19.","journal-title":"J Transl Med"},{"key":"2533_CR54","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ccr.2009.08.016","volume":"16","author":"L Wang","year":"2009","unstructured":"Wang L, Liu R, Li W, Chen C, Katoh H, Chen G, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009;16:336\u201346.","journal-title":"Cancer Cell"},{"key":"2533_CR55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3892\/mco.2013.107","volume":"1","author":"M Takenaka","year":"2013","unstructured":"Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H, Takahashi H, et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013;1:625\u201332.","journal-title":"Mol Clin Oncol"},{"key":"2533_CR56","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Dsis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"2533_CR57","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","volume":"27","author":"A Merlo","year":"2009","unstructured":"Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, M\u00e8nard S, Tagliabue E, Balsari A. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27:1746\u201352.","journal-title":"J Clin Oncol"},{"issue":"2553\u20132562","key":"2533_CR58","first-page":"71","volume":"8","author":"TK Hoffmann","year":"2002","unstructured":"Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8(2553\u20132562):71.","journal-title":"Clin Cancer Res"},{"issue":"3521\u20133529","key":"2533_CR59","first-page":"72","volume":"62","author":"TK Hoffmann","year":"2002","unstructured":"Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264\u2013272) peptide in the circulation of patients with head and neck cancer. Cancer Res. 2002;62(3521\u20133529):72.","journal-title":"Cancer Res"},{"key":"2533_CR60","first-page":"3137","volume":"8","author":"TE Reichert","year":"2002","unstructured":"Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res. 2002;8:3137\u201345.","journal-title":"Clin Cancer Res"},{"key":"2533_CR61","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","volume":"108","author":"ME Winerdal","year":"2010","unstructured":"Winerdal ME, Marits P, Winerdal M, Hasan M, Rosenblatt R, Tolf A, Selling K, Sherif A, Winqvist O. FOXP3 and survival in urinary bladder cancer. BJU Int. 2010;108:1672\u20138.","journal-title":"BJU Int"},{"key":"2533_CR62","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, Iked H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107\u201311.","journal-title":"Nature"},{"key":"2533_CR63","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","volume":"41","author":"SR Woo","year":"2014","unstructured":"Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leun MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41:830\u201342.","journal-title":"Immunity"},{"issue":"4","key":"2533_CR64","doi-asserted-by":"publisher","first-page":"106443","DOI":"10.1016\/j.isci.2023.106443","volume":"26","author":"T Trinh","year":"2023","unstructured":"Trinh T, Adams WA, Calescibetta A, Tu N, Dalton R, So T, Wei M, Ward G, Kostenko E, Christiansen S, Cen L, McLemore A, Reed K, Whitting J, Gilvary D, Blanco NL, Segura CM, Nguyen J, Kandell W, Chen X, Cheng P, Wright GM, Cress WD, Liu J, Wright KL, Wei S, Eksioglu EA. CX3CR1 deficiency-induced TIL tumor restriction as a novel addition for CAR-T design in solid malignancies. iScience. 2023;26(4):106443.","journal-title":"iScience."},{"issue":"1","key":"2533_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43046-024-00212-8","volume":"36","author":"SB Rejeb","year":"2024","unstructured":"Rejeb SB, Elfekih S, Kouki N, Boulma R, Khouni H. Immunochemistry-based quantification of tumor-infiltrating lymphocytes and immunoscore as prognostic biomarkers in bladder cancer. J Egypt Natl Canc Inst. 2024;36(1):9.","journal-title":"J Egypt Natl Canc Inst"},{"key":"2533_CR66","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26:259\u201371.","journal-title":"Ann Oncol"},{"key":"2533_CR67","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non\u2013small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 2017;24:311\u201335.","journal-title":"Adv Anat Pathol"},{"key":"2533_CR68","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci. 2007;104:3967\u201372.","journal-title":"Proc Natl Acad Sci"},{"key":"2533_CR69","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00345-012-0974-2","volume":"30","author":"W Otto","year":"2012","unstructured":"Otto W, Denzinger S, Wieland WF, Hartmann A. First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival. World J Urol. 2012;30:875\u20137.","journal-title":"World J Urol"},{"key":"2533_CR70","doi-asserted-by":"publisher","first-page":"327ra26","DOI":"10.1126\/scitranslmed.aad6352","volume":"8","author":"B Mlecnik","year":"2016","unstructured":"Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8:327ra26.","journal-title":"Sci Transl Med."}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02533-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02533-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02533-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T15:08:09Z","timestamp":1731510489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02533-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":70,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02533-z","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Ethics Committee of Universidade Estadual de Campinas (UNICAMP)\u2014(CAAE: 45218221.8.0000.5404) and by the Ethics Committee of Faculty of Medicine of Jundiai (CAAE: 45218221.8.3001.5412).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"287"}}